학술논문
For Type 2 Patients Requiring Basal Insulin Initiation, Insulin Detemir Offers the Flexibility of Once-Daily Dosing in the Morning or Evening: 3-Month Results from PREDICTIVE™.
Document Type
Article
Source
Subject
*TYPE 2 diabetes treatment
*PEOPLE with diabetes
*HYPOGLYCEMIC agents
*BODY weight
*HYPOGLYCEMIA
*CLINICAL trials
*EUROPEANS
*DISEASES
INSULIN therapy effectiveness
*
*
*
*
*
*
*
Language
ISSN
0012-1797
Abstract
The article focuses on the findings of the PREDICTIVE study which assessed the efficacy of insulin detemir initiation on type 2 diabetic patients in the European cohort. The subjects were switched from oral antidiabetic drugs (OADs) alone to once-daily insulin detemir ± OADs treatment. The groups which were divided based on taking the medication in the morning or in the evening showed improvements in glycemic control. There was no increased risk of hypoglycemia or weight gain found.